

FGF16 Antibody (N-term) Blocking peptide Synthetic peptide Catalog # BP11862a

Specification

FGF16 Antibody (N-term) Blocking peptide - Product Information

Primary Accession

<u>043320</u>

FGF16 Antibody (N-term) Blocking peptide - Additional Information

Gene ID 8823

Other Names Fibroblast growth factor 16, FGF-16, FGF16

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FGF16 Antibody (N-term) Blocking peptide - Protein Information

Name FGF16

Function Plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation, and is required for normal cardiomyocyte proliferation and heart development.

Cellular Location Secreted {ECO:0000250|UniProtKB:054769}.

FGF16 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• **Blocking Peptides**

FGF16 Antibody (N-term) Blocking peptide - Images

FGF16 Antibody (N-term) Blocking peptide - Background

The protein encoded by this gene is a subunit of themultisubunit NADH: ubiquinone oxidoreductase



(complex I). Mammaliancomplex I is composed of 45 different subunits. It locates at themitochondrial inner membrane. This protein has NADH dehydrogenaseactivity and oxidoreductase activity. It transfers electrons fromNADH to the respiratory chain. The immediate electron acceptor forthe enzyme is believed to be ubiquinone.

FGF16 Antibody (N-term) Blocking peptide - References

Saito, A., et al. J. Hum. Genet. 54(6):317-323(2009)Martins-de-Souza, D., et al. J Neural Transm 116(3):275-289(2009)Wang, L., et al. Cancer Epidemiol. Biomarkers Prev. 17(12):3558-3566(2008)Starr, J.M., et al. Mech. Ageing Dev. 129(12):745-751(2008)Lamesch, P., et al. Genomics 89(3):307-315(2007)